The effect of an autologous cellular gel-matrix integrated implant system on wound healing.
BACKGROUND
This manuscript reports the production and preclinical studies to examine the tolerance and efficacy of an autologous cellular gel-matrix integrated implant system (IIS) aimed to treat full-thickness skin lesions.


METHODS
The best concentration of fibrinogen and thrombin was experimentally determined by employing 28 formula ratios of thrombin and fibrinogen and checking clot formation and apparent stability. IIS was formed by integrating skin cells by means of the in situ gelification of fibrin into a porous crosslinked scaffold composed of chitosan, gelatin and hyaluronic acid. The in vitro cell proliferation within the IIS was examined by the MTT assay and PCNA expression. An experimental rabbit model consisting of six circular lesions was utilized to test each of the components of the IIS. Then, the IIS was utilized in an animal model to cover a 35% body surface full thickness lesion.


RESULTS
The preclinical assays in rabbits demonstrated that the IIS was well tolerated and also that IIS-treated rabbit with lesions of 35% of their body surface, exhibited a better survival rate (p = 0,06).


CONCLUSIONS
IIS should be further studied as a new wound dressing which shows promising properties, being the most remarkable its good biological tolerance and cell growth promotion properties.
Weinstein-Oppenheimer
Caroline R
CR
Departamento de Bioquímica, Facultad de Farmacia, Universidad de Valparaíso, Avenida Gran Bretaña 1093, Playa Ancha Valparaíso, Casilla 5001-V, Valparaíso, Chile. caroline.weinstein@uvach.cl
Aceituno
Alexis R
AR
Brown
Donald I
DI
Acevedo
Cristian
C
Ceriani
Ricardo
R
Fuentes
Miguel A
MA
Albornoz
Fernando
F
Henríquez-Roldán
Carlos F
CF
Morales
Patricio
P
Maclean
Claudio
C
Tapia
Sergio M
SM
Young
Manuel E
ME
D000818:Animals; D001681:Biological Assay; D001777:Blood Coagulation / Q000187:drug effects; D049109:Cell Proliferation / Q000187:drug effects; D002470:Cell Survival / Q000187:drug effects; D005340:Fibrinogen / Q000378:metabolism; D005782:Gels / Q000494:pharmacology*; D007150:Immunohistochemistry; D020007:Implants, Experimental; D018809:Proliferating Cell Nuclear Antigen / Q000378:metabolism; D011817:Rabbits; D012867:Skin / Q000187:drug effects / Q000473:pathology; D013917:Thrombin / Q000378:metabolism; D016896:Treatment Outcome; D014945:Wound Healing / Q000187:drug effects*
D005782:Gels; D018809:Proliferating Cell Nuclear Antigen; D005340:Fibrinogen; D013917:Thrombin